David Mulham Mulham Sells 3,234 Shares of USANA Health Sciences, Inc. (NYSE:USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNA) insider David Mulham Mulham sold 3,234 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $32.98, for a total value of $106,657.32. Following the sale, the insider now directly owns 12,775 shares of the company’s stock, valued at approximately $421,319.50. The trade was a 20.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

USANA Health Sciences Stock Down 1.9 %

Shares of USNA opened at $32.49 on Thursday. The stock has a market capitalization of $619.32 million, a P/E ratio of 11.48, a P/E/G ratio of 0.93 and a beta of 0.98. USANA Health Sciences, Inc. has a twelve month low of $27.71 and a twelve month high of $50.32. The company has a 50 day moving average of $32.86 and a 200-day moving average of $36.08.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.49 by $0.15. The company had revenue of $213.61 million during the quarter, compared to the consensus estimate of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. On average, sell-side analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on USNA. Sidoti cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th. StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Finally, DA Davidson decreased their price target on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday, February 27th.

Institutional Investors Weigh In On USANA Health Sciences

Large investors have recently made changes to their positions in the stock. R Squared Ltd acquired a new stake in shares of USANA Health Sciences in the 4th quarter valued at approximately $28,000. Safe Harbor Fiduciary LLC acquired a new stake in shares of USANA Health Sciences in the 3rd quarter valued at approximately $30,000. KBC Group NV boosted its holdings in shares of USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of USANA Health Sciences in the 4th quarter valued at approximately $83,000. Finally, Quantbot Technologies LP acquired a new stake in shares of USANA Health Sciences in the 4th quarter valued at approximately $132,000. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.